According to new research, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) -- including both accelerated or myeloid blast phases of the ...
"These findings indicate that frailty is a strong independent predictor for adverse in-patient outcomes in hospitalized CML patients . . . Frailty not only poses greater risk for in-hospital death in ...
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2016" report to their offering. This ...
The company announced that data from the ongoing CARDINAL trial of TERN-701 in participants with previously treated chronic myeloid leukemia (CML) will be presented at the 67th American Society of ...
A lower number of CD26+ LSCs at diagnosis correlates with optimal molecular response in CML patients at 3, 12, and 24 months.
Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced ...
Chronic myeloid leukemia (CML) is a type of blood cancer. CML is Philadelphia chromosome-positive (Ph+) when pieces of chromosomes 9 and 22 break off and swap places. This creates a new abnormal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback